Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia

Atherosclerosis

Volumn 144, Issue 1, 1999, Pages 167-175

  Winkler, K ^a,b   Schafer J R ^a   Klima, B ^a   Nuber, C ^a   Sattler, A ^a   Friedrich, I ^a   Koster W ^a   Steinmetz, A ^a   Wieland, H ^a   Marz W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cholesterol lowering drugs; In vivo kinetics; LDL receptor; Stable isotopes

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; LIFIBROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KINETICS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BUTANOLS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYBENZOIC ACIDS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0344417843     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00051-9     Document Type: Article

References (35)

1. Pederson TR, Kjekshus J, Berg K, Haghfelt T, Faeremann O, Thorgeirsson G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Scandinavian Simvastatin Survival Study Group. Lancet 1994;344:1383-1389.
2. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effects of pravastatin on the coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl Med 1996;335:1001-9.
4. Grundy SM. HMG-CoA reductase inhibitors for the treatment of hypercholesterolaemia. N Engl Med 1988;319:24-32.
5. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-82.
6. Hashim SA, van Itallie TB. Cholestyramine resin therapy for hypercholesterolaemia. J Am Med Assoc 1965;192:289-92.
7. Best MM, Duncan CH, van Loon EJ, Wathen JD. The effects of sitosterol on serum lipids. Am J Med 1956;45:614-22.
8. Staels B, van Toi A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 1992;12:286-94.
9. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
10. Schliack M, Löser R, Seibel K, Blay KH. Hypolipidaemic activity of K12.148 in rats, marmosets and pigs. Artery 1989;16:90-104.
11. Locker PK, Jungbluth GL, Francom SF, Hughes GS, for the Lifibrol study group. Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolaemia. Clin Pharmacol Ther 1995;57:73-88.
12. Scharnagl H, März W, Wieland H. Lifibrol: first member of a new class of lipid-lowering drugs? Exp Opin Invest Drugs 1997;6:583-91.
13. Schaefer JR, Rader DJ, Ikewaki K, Fairwell T, Zech LA, Kindt MR, Davignon J, Gregg RE, Brewer HB. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992;12:843-8.
14. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, März W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vase Biol 1997:17:348-53.
15. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955;34:1345-53.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
17. Cobelli CC, Toffolo G, Foster DM. Tracer to tracee ratio for analysis of stable isotope tracer data: link with radiotracer formalism. Am J Physiol 1992;262:E968-75.
18. Schaefer JR, Rader DJ, Brewer HB Jr. Investigation of lipo-protein kinetics using endogenous labeling with stable isotopes. Curr Opin Lipidol 1992;3:227-32.
19. Cobelli C, Toffolo G, Bier DM, Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am J Physiol 1987;253:E551-64.
20. SAAM Institute Inc. SAAM II User Guide. Seattle, Washington: SAAM Institute Inc; 1997.
21. Maugeais C, Braschi S, Ouguerram K, Maugeais P, Mahot P, Jacotot B, Darmaun D, Magot T, Krempf M. Lipoprotein Kinetics in patients with analbuminemia. Arteriol Thromb Vase Biol 1997;17:1369-75.
22. Parhofer KG, Barren PHR, Bier DM, Schonfeld G. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes. J Lipid Res 1991;32:1311-23.
23. Parhofer KG, Barren PHR, Bier DM, Schonfeld G. Lipoproteins containing the truncated apolipoprotein, apo B-89, are cleared from human plasma more rapidly than apo B-100-containing lipoproteins in vivo. J Clin Invest 1992;89:1931-7.
24. Krul ES, Parhofer KG, Barren PHR, Wagner RD, Schonfeld G. ApoB-75, a truncation of apolipoprotein B associated with familial hypobetalipoproteinemia: genetic and kinetic studies. J Lipid Res 1992:33:1037-50.
25. Aguilar-Salinas CA, Barren PHR, Parhofer KG, Young SG, Tessereau D, Bateman J, Quinn C, Schonfeld G. Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B. Arterioscler Thromb Vase Biol 1995:15:71-80.
26. Welty FK, Lichtenstein AH, Barren PHR, Dolnikowski GG, Ordovas JM, Schaefer EJ. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B100 heterozygotes. Arterioscler Thromb Vasc Biol 1997;17:8818.
27. Hasibeder H, Staab HJ, Seibel K, Heibel B, Schmidle G, März W. Clinical pharmacology of the hypocholesterolemic agent K12.148 (Lifibrol) in healthy volunteers. Eur J Clin Pharmacol 1991;40(Suppl. l):S91-4.
28. Vega G, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. J Am Med Assoc 1985;253:2398-403.
29. Vega G, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 1988:33:1160-8.
30. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Int Med 1990:227:81-94.
31. Aguilar-Salinas CA, Barren PHR, Kelber J, Delmez J, Schonfeld G. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J Lipid Res 1995;36:188-99.
32. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb 1993; 13:170-89.
33. Vega G, Grundy SM. Influence of Lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia. J Int Med 1991;230:341-9.
34. Parhofer KG, Barren PHR, Dunn J, Schonfeld G. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia. Clin Invest 1993:71:939-46.
35. Aguilar-Salinas CA, Barren PHR, Pulai J, Zhu XL, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and Pravastatin therapy. Arterioscler Thromb Vase Biol 1997:17:72-82.